NASDAQ:DERM - Dermira Stock Price, Price Target & More

$8.92 +0.31 (+3.60 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$8.92
Today's Range$8.47 - $8.92
52-Week Range$6.98 - $34.45
Volume710,200 shs
Average Volume953,927 shs
Market Capitalization$360.09 million
P/E Ratio-2.03
Dividend YieldN/A
Beta1.52

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200

Debt

Debt-to-Equity Ratio1.87%
Current Ratio5.28%
Quick Ratio5.28%

Price-To-Earnings

Trailing P/E Ratio-2.03
Forward P/E Ratio-1.85
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.54 million
Price / Sales82.17
Cash FlowN/A
Price / CashN/A
Book Value$3.59 per share
Price / Book2.48

Profitability

EPS (Most Recent Fiscal Year)($4.39)
Net Income$-303,260,000.00
Net Margins-6,678.29%
Return on Equity-62.07%
Return on Assets-29.13%

Miscellaneous

Employees162
Outstanding Shares41,820,000

How to Become a New Pot Stock Millionaire

Dermira (NASDAQ:DERM) Frequently Asked Questions

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira (NASDAQ:DERM) released its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts' consensus estimates of ($1.25) by $0.09. The biopharmaceutical company had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million. Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. View Dermira's Earnings History.

What price target have analysts set for DERM?

7 brokerages have issued 1 year price objectives for Dermira's stock. Their predictions range from $19.00 to $48.00. On average, they expect Dermira's share price to reach $32.7143 in the next year. View Analyst Ratings for Dermira.

What are Wall Street analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:
  • 1. Cantor Fitzgerald analysts commented, "We remain positive on DERM’s stock following a group investor dinner we held on 3/26/18 with COO & CFO Andrew Guggenhime and VP of IR Ian Clements." (3/27/2018)
  • 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (3/16/2018)
  • 3. Mizuho analysts commented, "We can attest that Dermira has been investing in pre-launch activities and had a strong presence at the AAD 2018 conference across all three of its key assets in acne, hyperhidrosis, and atopic dermatitis. We summarize 4Q:17 results in Exhibit 1 below. We reiterate our Buy rating in front of the binary acne read-out, which if positive, could drive significant upside to the stock. Data are expected in 1Q:18." (2/23/2018)

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:
  • Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)
  • Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)
  • Mr. Christopher M. Griffith, Co-Founder & Sr. VP of Corp. Devel. & Strategy (Age 42)
  • Mr. Andrew L. Guggenhime, COO, CFO & Principal Accounting Officer (Age 50)
  • Mr. Luis C. Peña, Chief Devel. Officer (Age 55)

Has Dermira been receiving favorable news coverage?

Press coverage about DERM stock has trended somewhat positive on Saturday, Accern reports. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dermira earned a news sentiment score of 0.21 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.72 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Dermira's major shareholders?

Dermira's stock is owned by a number of of retail and institutional investors. Top institutional investors include WELLINGTON MANAGEMENT GROUP LLP (10.50%), PRUDENTIAL FINANCIAL INC (2.30%) and FMR LLC (0.30%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.

How do I buy shares of Dermira?

Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $8.92.

How big of a company is Dermira?

Dermira has a market capitalization of $360.09 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]


MarketBeat Community Rating for Dermira (DERM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dermira (NASDAQ:DERM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Dermira in the last 12 months. Their average twelve-month price target is $32.7143, suggesting that the stock has a possible upside of 266.75%. The high price target for DERM is $48.00 and the low price target for DERM is $19.00. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.712.712.502.25
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.7143$32.7143$42.1667$44.40
Price Target Upside: 266.75% upside292.73% upside56.40% upside72.16% upside

Dermira (NASDAQ:DERM) Consensus Price Target History

Price Target History for Dermira (NASDAQ:DERM)

Dermira (NASDAQ:DERM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018Cantor FitzgeraldSet Price TargetBuy$20.00MediumView Rating Details
3/22/2018Leerink SwannReiterated RatingOutperformLowView Rating Details
3/6/2018Needham & Company LLCLower Price TargetBuy$43.00 -> $19.00HighView Rating Details
3/6/2018GuggenheimDowngradeBuy -> NeutralHighView Rating Details
3/5/2018MizuhoDowngradeBuy -> NeutralN/AView Rating Details
3/5/2018CowenSet Price TargetBuy$25.00N/AView Rating Details
6/29/2017Evercore ISIInitiated CoverageOutperform$48.00MediumView Rating Details
3/16/2017Raymond JamesInitiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017CitigroupInitiated CoverageUnderperformHighView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Dermira (NASDAQ:DERM) Earnings History and Estimates Chart

Earnings by Quarter for Dermira (NASDAQ:DERM)

Dermira (NASDAQ:DERM) Earnings Estimates

2018 EPS Consensus Estimate: ($5.17)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.40)($1.40)($1.40)
Q2 20181($1.19)($1.19)($1.19)
Q3 20181($1.24)($1.24)($1.24)
Q4 20181($1.34)($1.34)($1.34)

Dermira (NASDAQ DERM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018Q4 2017($1.2460)($1.34)$1.10 million$1.34 millionViewN/AView Earnings Details
11/6/2017Q3 2017($1.12)($1.21)$1.05 million$1.07 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.8860)($0.93)$1.00 million$1.07 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.86)($0.79)$1.07 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.93)($0.2070)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
3/3/2016Q4 2015($1.00)($0.99)ViewN/AView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
11/12/2014Q3 2014($0.67)($8.66)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Dermira (NASDAQ:DERM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Dermira (NASDAQ DERM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 94.93%
Insider Trading History for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Dermira (NASDAQ DERM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2018David E CohenDirectorSell600$25.85$15,510.00View SEC Filing  
3/1/2018Eugene A BauerInsiderSell500$25.32$12,660.00View SEC Filing  
2/1/2018David E CohenDirectorSell600$28.87$17,322.0030,282View SEC Filing  
2/1/2018Eugene A BauerInsiderSell3,000$28.55$85,650.005,802View SEC Filing  
1/2/2018Christopher M GriffithSVPSell18,458$27.05$499,288.90View SEC Filing  
1/2/2018David E CohenDirectorSell600$28.03$16,818.00View SEC Filing  
1/2/2018Eugene A BauerInsiderSell3,000$27.07$81,210.005,802View SEC Filing  
12/18/2017Eugene A. BauerInsiderSell3,000$27.34$82,020.00View SEC Filing  
12/13/2017Thomas G. WiggansCEOSell5,000$27.51$137,550.00View SEC Filing  
12/1/2017David E CohenDirectorSell600$25.49$15,294.00View SEC Filing  
11/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
11/1/2017David E CohenDirectorSell600$26.82$16,092.00View SEC Filing  
10/11/2017Eugene A BauerInsiderSell7,500$30.04$225,300.00View SEC Filing  
10/10/2017Thomas G WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
10/2/2017David E CohenDirectorSell600$26.99$16,194.0032,682View SEC Filing  
9/18/2017Thomas G. WiggansCEOSell9,500$27.51$261,345.00View SEC Filing  
9/1/2017David E CohenDirectorSell600$23.56$14,136.0033,282View SEC Filing  
8/28/2017David E CohenDirectorSell600$23.81$14,286.0033,882View SEC Filing  
8/14/2017Fred B CravesDirectorBuy30,000$23.03$690,900.00View SEC Filing  
8/1/2017Thomas G. WiggansCEOSell500$27.58$13,790.00View SEC Filing  
7/5/2017Eugene A BauerInsiderSell2,500$30.00$75,000.00View SEC Filing  
7/3/2017Thomas G. WiggansCEOSell5,000$29.06$145,300.00View SEC Filing  
6/20/2017Eugene A BauerInsiderSell2,500$30.01$75,025.00View SEC Filing  
6/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.0014,468View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00500View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.0017,468View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00500View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00500View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.0011,468View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00500View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00125View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00375View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.009,216View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00500View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.9945,165View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.0016,016View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00500View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.0020,116View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.7845,165View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.0015,116View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00500View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.2544,941View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.0014,375View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00500View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.0644,941View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.0014,375View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.0014,653View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.007,653View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.8048,043View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dermira (NASDAQ DERM) News Headlines

Source:
DateHeadline
Dermira (DERM) Lifted to Buy at BidaskClubDermira (DERM) Lifted to Buy at BidaskClub
www.americanbankingnews.com - April 20 at 12:41 PM
Christopher Horan Joins Dermira as Chief Technical Operations OfficerChristopher Horan Joins Dermira as Chief Technical Operations Officer
finance.yahoo.com - April 19 at 5:20 PM
Dermira (DERM) Given Average Rating of "Hold" by BrokeragesDermira (DERM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 11:30 AM
Dermira (DERM) Rating Increased to Sell at BidaskClubDermira (DERM) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - April 17 at 9:57 AM
Dermira (DERM) Downgraded by BidaskClubDermira (DERM) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM
Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment ...Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment ...
globenewswire.com - April 13 at 5:14 PM
Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 12 at 9:14 AM
Zacks: Analysts Expect Dermira (DERM) to Announce -$1.29 EPSZacks: Analysts Expect Dermira (DERM) to Announce -$1.29 EPS
www.americanbankingnews.com - April 11 at 1:08 AM
BidaskClub Downgrades Dermira (DERM) to Strong SellBidaskClub Downgrades Dermira (DERM) to Strong Sell
www.americanbankingnews.com - April 10 at 10:00 PM
Dermira (DERM) Stock Rating Lowered by BidaskClubDermira (DERM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 10:24 AM
Dermira (DERM) Given a $20.00 Price Target at Cantor FitzgeraldDermira (DERM) Given a $20.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 9 at 8:25 AM
Dermiras (DERM) Buy Rating Reaffirmed at Needham & Company LLCDermira's (DERM) Buy Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - April 1 at 4:16 PM
Dermira (DERM) Given "Outperform" Rating at Leerink SwannDermira (DERM) Given "Outperform" Rating at Leerink Swann
www.americanbankingnews.com - April 1 at 3:42 PM
Dermira (DERM) Downgraded by Zacks Investment Research to "Sell"Dermira (DERM) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 31 at 4:56 PM
BidaskClub Downgrades Dermira (DERM) to HoldBidaskClub Downgrades Dermira (DERM) to Hold
www.americanbankingnews.com - March 30 at 9:27 AM
Cantor Fitzgerald Reaffirms "Buy" Rating for Dermira (DERM)Cantor Fitzgerald Reaffirms "Buy" Rating for Dermira (DERM)
www.americanbankingnews.com - March 27 at 9:31 AM
Dermira (DERM) Upgraded by BidaskClub to BuyDermira (DERM) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 26 at 2:30 PM
Q1 2018 Earnings Forecast for Dermira Inc (DERM) Issued By Leerink SwannQ1 2018 Earnings Forecast for Dermira Inc (DERM) Issued By Leerink Swann
www.americanbankingnews.com - March 26 at 1:04 AM
Dermira (DERM) Downgraded to "Hold" at BidaskClubDermira (DERM) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 25 at 3:12 PM
Dermira Inc (DERM) Expected to Announce Earnings of -$1.29 Per ShareDermira Inc (DERM) Expected to Announce Earnings of -$1.29 Per Share
www.americanbankingnews.com - March 25 at 3:12 AM
BidaskClub Lowers Dermira (DERM) to SellBidaskClub Lowers Dermira (DERM) to Sell
www.americanbankingnews.com - March 24 at 1:11 PM
Dermira Inc (DERM) Given Consensus Recommendation of "Buy" by BrokeragesDermira Inc (DERM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 24 at 11:56 AM
Dermira (DERM) Downgraded by GuggenheimDermira (DERM) Downgraded by Guggenheim
www.americanbankingnews.com - March 24 at 11:24 AM
Dermiras (DERM) Outperform Rating Reaffirmed at Leerink SwannDermira's (DERM) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - March 24 at 10:49 AM
Dermira (DERM) vs. Fibrocell Science (FCSC) Financial ReviewDermira (DERM) vs. Fibrocell Science (FCSC) Financial Review
www.americanbankingnews.com - March 23 at 3:26 AM
Dermira to Present at 17th Annual Needham Healthcare ConferenceDermira to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 8:51 AM
Dermira (DERM) Raised to Hold at BidaskClubDermira (DERM) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 17 at 6:14 PM
Dermira (DERM) Upgraded at Zacks Investment ResearchDermira (DERM) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 16 at 8:21 PM
Wired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung CancerWired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer
finance.yahoo.com - March 14 at 6:40 PM
FY2018 EPS Estimates for Dermira Inc Lowered by Analyst (DERM)FY2018 EPS Estimates for Dermira Inc Lowered by Analyst (DERM)
www.americanbankingnews.com - March 9 at 10:35 AM
Dermira (DERM) Rating Lowered to Sell at Zacks Investment ResearchDermira (DERM) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 8 at 9:58 PM
Dermira Inc (DERM) Expected to Post Q1 2018 Earnings of ($1.40) Per ShareDermira Inc (DERM) Expected to Post Q1 2018 Earnings of ($1.40) Per Share
www.americanbankingnews.com - March 8 at 6:28 AM
Dermira Reminds Investors What Binary Means in BiotechDermira Reminds Investors What Binary Means in Biotech
finance.yahoo.com - March 6 at 5:25 PM
US Stocks Reverse LossesUS Stocks Reverse Losses
finance.yahoo.com - March 6 at 5:25 PM
Here's Why Dermira Fell as Much as 64.2% TodayHere's Why Dermira Fell as Much as 64.2% Today
finance.yahoo.com - March 6 at 5:25 PM
Why This Biotech Stock Just Lost Two-Thirds Of Its ValueWhy This Biotech Stock Just Lost Two-Thirds Of Its Value
finance.yahoo.com - March 6 at 5:25 PM
Dermira (DERM) Price Target Cut to $19.00Dermira (DERM) Price Target Cut to $19.00
www.americanbankingnews.com - March 6 at 3:29 PM
Here’s What Really Just Happened With Dermira, Inc. (NASDAQ:DERM)Here’s What Really Just Happened With Dermira, Inc. (NASDAQ:DERM)
finance.yahoo.com - March 6 at 8:36 AM
AWM Investment Company Inc. Has $2.80 Million Stake in Dermira Inc (DERM)AWM Investment Company Inc. Has $2.80 Million Stake in Dermira Inc (DERM)
www.americanbankingnews.com - March 6 at 4:45 AM
Dermira (DERM) Says Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary EndpointsDermira (DERM) Says Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
www.streetinsider.com - March 5 at 5:36 PM
Dermira abandons acne drugDermira abandons acne drug
www.reuters.com - March 5 at 5:36 PM
Why Dermira Shares Are Getting CrushedWhy Dermira Shares Are Getting Crushed
247wallst.com - March 5 at 5:36 PM
Dermira Inc (DERM) Runs Downhill on Back of Disappointing Clinical Results in Acne VulgarisDermira Inc (DERM) Runs Downhill on Back of Disappointing Clinical Results in Acne Vulgaris
finance.yahoo.com - March 5 at 5:36 PM
Dermira (DERM) Rating Lowered to Neutral at MizuhoDermira (DERM) Rating Lowered to Neutral at Mizuho
www.americanbankingnews.com - March 5 at 1:58 PM
Cowen Analysts Give Dermira (DERM) a $25.00 Price TargetCowen Analysts Give Dermira (DERM) a $25.00 Price Target
www.americanbankingnews.com - March 5 at 1:36 PM
Dermira Inc Stock Plunges on Acne Drug FailureDermira Inc Stock Plunges on Acne Drug Failure
investorplace.com - March 5 at 1:19 PM
Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary EndpointsDermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
finance.yahoo.com - March 5 at 8:40 AM
Dermira shares plummet 70% on news of acne drug failureDermira shares plummet 70% on news of acne drug failure
finance.yahoo.com - March 5 at 8:40 AM
Dermira Inc (DERM) Director Sells $15,510.00 in StockDermira Inc (DERM) Director Sells $15,510.00 in Stock
www.americanbankingnews.com - March 2 at 7:36 PM
Dermira Inc (DERM) Insider Eugene A. Bauer Sells 500 SharesDermira Inc (DERM) Insider Eugene A. Bauer Sells 500 Shares
www.americanbankingnews.com - March 2 at 7:34 PM

SEC Filings

Dermira (NASDAQ:DERM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dermira (NASDAQ:DERM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dermira (NASDAQ DERM) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.